Literature DB >> 17101506

Paraneoplastic autoimmune multiorgan syndrome: review of the literature and support for a cytotoxic role in pathogenesis.

Sara E Billet1, Sergei A Grando, Mark R Pittelkow.   

Abstract

Paraneoplastic autoimmune multiorgan syndrome (PAMS), first described as paraneoplastic pemphigus in 1990, is an autoimmune blistering disease associated with neoplasia. Patients with this rare disorder have severe blistering and painful erosions of the oral cavity and various other cutaneous findings ranging from classic pemphigus vulgaris-like erosions to targetoid lesions resembling erythema multiforme and papular to more confluent lichenoid eruptions. This syndrome involves multiple organ systems, and its high rate of mortality often stems from constrictive bronchiolitis obliterans. The histologic findings are as diverse as the clinical presentation, often making diagnosis difficult initially. Immunodermatologic and serologic laboratory findings typically establish the diagnosis. These results can be confirmed with immunoprecipitation profiling of specific molecular weight protein markers. The proposed pathogenesis of PAMS continues to evolve, and recent reports implicate the involvement of cell-mediated, cytotoxic immunity, in addition to humoral autoantibodies. This review characterizes and summarizes the clinical, pathologic, and immunohistologic features of PAMS and outlines the possible role of cytotoxic T lymphocytes in the pathogenesis of this syndrome.

Entities:  

Mesh:

Year:  2006        PMID: 17101506     DOI: 10.1080/08916930600972099

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  14 in total

Review 1.  A Systematic Review of Patients with Mucocutaneous and Respiratory Complications in Paraneoplastic Autoimmune Multiorgan Syndrome: Castleman's Disease is the Predominant Malignancy.

Authors:  John Lee; Romi Bloom; Kyle T Amber
Journal:  Lung       Date:  2015-04-23       Impact factor: 2.584

Review 2.  The etiology of paraneoplastic autoimmunity.

Authors:  Emanual Maverakis; Heidi Goodarzi; Lisa N Wehrli; Yoko Ono; Miki Shirakawa Garcia
Journal:  Clin Rev Allergy Immunol       Date:  2012-04       Impact factor: 8.667

3.  The protease inhibitor alpha-2-macroglobulin-like-1 is the p170 antigen recognized by paraneoplastic pemphigus autoantibodies in human.

Authors:  Isabelle Schepens; Fabienne Jaunin; Nadja Begre; Ursula Läderach; Katrin Marcus; Takashi Hashimoto; Bertrand Favre; Luca Borradori
Journal:  PLoS One       Date:  2010-08-18       Impact factor: 3.240

Review 4.  Pemphigus autoimmunity: hypotheses and realities.

Authors:  Sergei A Grando
Journal:  Autoimmunity       Date:  2011-09-23       Impact factor: 2.815

5.  Rituximab in severe skin diseases: target, disease, and dose.

Authors:  Daniel D Bennett; Maro Ohanian; Christian T Cable
Journal:  Clin Pharmacol       Date:  2010-07-07

6.  Proliferative response of peripheral blood mononuclear cells in anti-Hu antibody-associated patients with paraneoplastic neurological syndrome and their depressant effect on small cell lung cancer cells.

Authors:  Liang Yin; Hongdang Qu; Qiming Chen
Journal:  Mol Med Rep       Date:  2014-11-19       Impact factor: 2.952

Review 7.  Paraneoplastic Pemphigus: Insight into the Autoimmune Pathogenesis, Clinical Features and Therapy.

Authors:  Giovanni Paolino; Dario Didona; Giuseppe Magliulo; Giannicola Iannella; Biagio Didona; Santo Raffaele Mercuri; Elisa Moliterni; Michele Donati; Andrea Ciofalo; Guido Granata; Patricia Ranuzzi; Vincenzo Falasca; Stefano Calvieri
Journal:  Int J Mol Sci       Date:  2017-11-26       Impact factor: 5.923

8.  Paraneoplastic Pemphigus: An Indication for Treatment in Chronic Lymphocytic Leukemia.

Authors:  Ifeanyichukwu Onukogu; Preethi Ramachandran; Joshua Narh; Sonu Sahni; Gardith Joseph
Journal:  Cureus       Date:  2020-05-27

Review 9.  Immunopathology and molecular diagnosis of autoimmune bullous diseases.

Authors:  Sidonia Mihai; Cassian Sitaru
Journal:  J Cell Mol Med       Date:  2007 May-Jun       Impact factor: 5.310

10.  High-dose-rate intraluminal brachytherapy for paraneoplastic autoimmune multiorgan syndrome.

Authors:  Sun-Young Lee; Jong-Hyun Kim; Dong-Hyu Cho
Journal:  Exp Ther Med       Date:  2016-06-15       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.